Shamburg News · 8-K filed Oct 23, 2026, 8:00 AM EDT
ORIC Pharmaceuticals Presents Enozertinib Phase 1b Update at ESMO 2026, Plans Phase 3 in 2027
ORIC · Oric Pharmaceuticals, Inc.
- Other event
- Reg FD disclosure
- Materiality: medium
ORIC Pharmaceuticals, Inc. presented an enozertinib (ORIC-114) program update on October 23, 2026 at ESMO Congress 2026, furnished as Exhibit 99.1. The Phase 1b data for 26 patients with 1L EGFR atypical NSCLC reported an 84% confirmed systemic ORR by investigator, a 70% confirmed intracranial ORR by investigator, and six-month landmark PFS of 88%. The Company stated it plans to initiate the global Phase 3 Redwood-1 trial in the first half of 2027.
Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, accession 0001193125-26-429465.
Written from the filing by Shamburg Markets. Figures are as reported by the company.